Very low-intensity antithrombotic therapy in atrial fibrillation

Journal of Thrombosis and Thrombolysis

Volumn 7, Issue 1, 1999, Pages 67-71

  Koefoed, Birgitte Gade ^a   Petersen, Palle ^b  

^a Sundhedsstyrelsen   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; THROMBIN; WARFARIN;

ARTICLE; DIABETES MELLITUS; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK ASSESSMENT; RISK FACTOR; SENESCENCE; SINUS RHYTHM; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HUMANS; WARFARIN;

EID: 0033060737     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008835505438     Document Type: Article

References (33)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469-473.
2. Godtfredsen J. Atrial fibrillation: Course and prognosis - a follow-up study of 1212 cases (Thesis). Munksgaard, Copenhagen 1975.
3. Gustafsson C, Britton M. Pathogenetic mechanism of stroke in non-valvular atrial fibrillation: Follow-up of stroke patients with and without atrial fibrillation. Intern Med 1991;230:11-16.
4. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation. The Framingham Study. N Engl J Med 1982;306:1018-1022.
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke 1991;22:983-988.
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly. Arch Intern Med 1987;147:1561-1564.
7. Britton M, Gustafsson C. Non-rheumatic atrial fibrillation as a risk factor for stroke. Stroke 1985;16:182-188.
8. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
9. Lin HL, Wolf PA, Kelley-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB. Stroke severity in atrial fibrillation. The Framingham study. Stroke 1996;27: 1760-1764.
10. Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. Stroke 1996; 10:1765-1769.
11. Petersen P, Godtfredsen J, Boysen G, Andersen ED, Andersen B. Placebo-controlled randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989:1:175-179.
12. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
13. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991;84:527-539.
14. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:149-155.
15. Ezekowitz MD, Briders SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-1412.
16. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691.
17. Meer FJM van der, Rosendaal FR, Vandenbroucke JP, Breit E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993;153: 1557-1562.
18. Poller L, McKernan A, Thomson JM, Elstein M, Hirsch PJ, Jones JB. Fixed minidose warfarin: A new approach to prophylaxis against venous thrombosis after major surgery. Br Med J 1987;295:1309-1312.
19. MacCallum PK, Thompson JM, Poller L. Effect of fixed minidose warfarin on coagulation and fibrinolysis following major gynaecological surgery. Thromb Haemost 1990;64: 511-515.
20. Bern MM, Lokich JJ, Wallach SR, et al. Very low dose of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 1990;112:423-428.
21. Bern M, Bierbaum B, Wetzner S. Fixed very low dose vs. variable dose warfarin for deep vein thrombosis (DVT) prophylaxis. Thromb Haemost 1997; 77(Supple.):82.
22. Millenson MM, Bauer KA, Kistler JP, Barzegar S, Tulin L, Rosenberg RD. Monitoring "mini-intensity" anticoagulation with warfarin: Comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment 1 + 2 levels. Blood 1992;79:2034-2038.
23. Yamanouichi H, Tomonaga M, Shimada H, Matsushita S, Kuramoto K, Toyokura Y. Nonvalvular atrial fibrillation as a cause of fatal massive cerebral infarction in the elderly. Stroke 1989;20:1653-1656.
24. Fuster V, Stein B, Halperin JL, Chesebro JH. Antithrombotic therapy in cardiac disease: An approach based on pathogenesis and risk stratification. Am J Cardiol 1990;65:38C-44C.
25. Primary preventive effects of anticoagulants and acetylsalicylic acid on arterial thromboembolism in patients with nonvalvular atrial fibrillation in general practice (PATAF). Abstract. Stroke 1993;10:1619.
26. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996;348:633-638.
27. Koefoed BG, Gulløv AL, Petersen P. The second Copenhagen Atrial Fibrillation, Aspirin and Anticoagulant Therapy Study (AFASAK 2): Methods and design. J Thrombos Thrombolys 1995;2:125-130.
28. Pengo V, Zasso A, Barbero F, Banzato A, Nante G, Parissenti L, John N, No venta F, Volta SD. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol 1998;82:433-437.
29. Meade TW. Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic heart disease. Am J Cardiol 1990;65:7C-11C.
30. Koefoed BG, Gulløv AL, Petersen P. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation. Thromb Haemost 1997;77:845-884.
31. Hylek EM, Skatts SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546.
32. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent ischemia. N Engl J Med 1995;333:5-10.
33. Gulløv AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, Boysen G. Fixed minidose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation. Second Copenhagen Atrial Fibrillation and Anticoagulation Study (AFASAK 2). Arch Intern Med 1998;158:1513-1521.